This Clive Meanwell + John Maraganore NewCo sounds epic... Putting $50M of their own capital into a moonshot to prevent cardiovascular disease. Lots of very ambitious takes on how biotech is changing, too: - Building an AI model to predict/assess a patient's cardiovascular health - From there, prescribe siRNA medicines (They apparently feel discovery is solved/commoditized, but manufacturing this much RNA for a common disease is one of the big open q's for the modality) - Envision a very different commercial trajectory with “very affordable cost that is very easy to access,” alluding to growth of direct-to-consumer—and even subscription—delivery models as the future plan. With all of the "$1T+ biotech" discourse ( @ladanuzhna ) I feel like AI prediction + genetic medicines + DTC run by two of the GOATs is a real contender for what this could look like...